Naringenin reduces lung metastasis in a breast cancer resection model

Abstract

Metastasis is the main cause of death in cancer patients. To improve the outcomes of patients undergoing a surgery, new adjuvant therapies that can effectively inhibit metastases have to be developed. Studies have shown that flavonoid naringenin, a natural product that is mainly present in grapes and citrus, may contribute to cancer prevention. It has many advantages compared to traditional chemotherapeutic drugs, such as low toxicity. To determine whether naringenin can also inhibit metastases, a breast cancer resection model that mimics clinical situations was established. We found that orally administered naringenin significantly decreased the number of metastatic tumor cells in the lung and extended the life span of tumor resected mice. Flow cytometry analysis revealed that T cells displayed enhanced antitumor activity in naringenin treated mice, with an increased proportion of IFN-γ and IL-2 expressing T cells. In vitro studies further demonstrated that relief of immunosuppression caused by regulatory T cells might be the fundamental mechanism of metastasis inhibition by naringenin. These results indicate that orally administered naringenin can inhibit the outgrowth of metastases after surgery via regulating host immunity. Thus, naringenin can be an ideal surgical adjuvant therapy for breast cancer patients.

Keywords

naringenin / breast cancer / surgery / metastasis / immunosuppression / Tregs

References

[1] Ben-Eliyahu, S. (2003). The promotion of tumor metastasis by surgery and stress: immunological basis and implications for psychoneuroimmunology. Brain Behav Immun 17, S27-S36 10.1016/S0889-1591(02)00063-6.
[2] Beyer, M., and Schultze, J.L. (2006). Regulatory T cells in cancer. Blood 108, 804-811 10.1182/blood-2006-02-002774.
[3] Bindea, G., Mlecnik, B., Fridman, W.H., Pages, F., and Galon, J. (2010). Natural immunity to cancer in humans. Curr Opin Immunol 22, 215-222 10.1016/j.coi.2010.02.006.
[4] Boomsma, M.F., Garssen, B., Slot, E., Berbee, M., Berkhof, J., Meezenbroek Ede, J., Slieker, W., Visser, A., Meijer, S., and Beelen, R.H. (2010). Breast cancer surgery-induced immunomodulation. J Surg Oncol 102, 640-648 10.1002/jso.21662.
[5] Brandacher, G., Winkler, C., Schroecksnadel, K., Margreiter, R., and Fuchs, D. (2006). Antitumoral activity of interferon-gamma involved in impaired immune function in cancer patients. Curr Drug Metab 7, 599-612 10.2174/138920006778017768.
[6] Brune, I.B., Wilke, W., Hensler, T., Holzmann, B., and Siewert, J.R. (1999). Downregulation of T helper type 1 immune response and altered pro-inflammatory and anti-inflammatory T cell cytokine balance following conventional but not laparoscopic surgery. Am J Surg 177, 55-60 10.1016/S0002-9610(98)00299-2.
[7] Chen, L., Huang, T.G., Meseck, M., Mandeli, J., Fallon, J., and Woo, S.L. (2007). Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Mol Ther 15, 2194-2202 10.1038/sj.mt.6300310.
[8] Chen, W.J., and Konkel, J.E. (2010). TGF-beta and 'Adaptive' Foxp3(+) Regulatory T cells. J Mol Cell Biol 2, 30-36 10.1093/jmcb/mjp004.
[9] Chiang, J.Y., Jang, I.K., Hodes, R., and Gu, H. (2007). Ablation of Cbl-b provides protection against transplanted and spontaneous tumors. J Clin Invest 117, 1029-1036 10.1172/JCI29472.
[10] Coffelt, S.B., Hughes, R., and Lewis, C.E. (2009). Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta 1796, 11-18 .
[11] Coughlin, S.S., and Ekwueme, D.U. (2009). Breast cancer as a global health concern. Cancer Epidemiol 33, 315-318 10.1016/j.canep.2009.10.003.
[12] Du, G., Jin, L., Han, X., Song, Z., Zhang, H., and Liang, W. (2009). Naringenin: a potential immunomodulator for inhibiting lung fibrosis and metastasis. Cancer Res 69, 3205-3212 10.1158/0008-5472.CAN-08-3393.
[13] duPre, S.A., Redelman, D., and Hunter, K.W. Jr. (2008). Microenvironment of the murine mammary carcinoma 4T1: endogenous IFN-gamma affects tumor phenotype, growth, and metastasis. Exp Mol Pathol 85, 174-188 10.1016/j.yexmp.2008.05.002.
[14] Faist, E., Kupper, T.S., Baker, C.C., Chaudry, I.H., Dwyer, J., and Baue, A.E. (1986). Depression of Cellular-Immunity after Major Injury- Its Association with Posttraumatic Complications and Its Reversal with Immunomodulation. Arch Surg-Chicago 121, 1000-1005 .
[15] Fang, F., Tang, Y., Gao, Z., and Xu, Q. (2010). A novel regulatory mechanism of naringenin through inhibition of T lymphocyte function in contact hypersensitivity suppression. Biochem Biophys Res Commun 397, 163-169 10.1016/j.bbrc.2010.05.065.
[16] Gabrilovich, D.I., and Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9, 162-174 10.1038/nri2506.
[17] Hogan, B.V., Peter, M.B., Shenoy, H.G., Horgan, K., and Hughes, T.A. (2011). Surgery induced immunosuppression. Surg-J R Coll Surg E 9, 38-43 .
[18] James, M.A., Lu, Y., Liu, Y., Vikis, H.G., and You, M. (2009). RGS17, an overexpressed gene in human lung and prostate cancer, induces tumor cell proliferation through the cyclic AMP-PKA-CREB pathway. Cancer Res 69, 2108-2116 10.1158/0008-5472.CAN-08-3495.
[19] Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010). Cancer statistics, 2010. CA Cancer J Clin 60, 277-300 10.3322/caac.20073.
[20] Kanno, S., Tomizawa, A., Hiura, T., Osanai, Y., Shouji, A., Ujibe, M., Ohtake, T., Kimura, K., and Ishikawa, M. (2005). Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice. Biol Pharm Bull 28, 527-530 10.1248/bpb.28.527.
[21] Ko, K., Yamazaki, S., Nakamura, K., Nishioka, T., Hirota, K., Yamaguchi, T., Shimizu, J., Nomura, T., Chiba, T., and Sakaguchi, S. (2005). Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 202, 885-891 10.1084/jem.20050940.
[22] Kong, L.Y., Wei, J., Sharma, A.K., Barr, J., Abou-Ghazal, M.K., Fokt, I., Weinberg, J., Rao, G., Grimm, E., Priebe, W., (2009). A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother 58, 1023-1032 10.1007/s00262-008-0618-y.
[23] Le Marchand, L., Murphy, S.P., Hankin, J.H., Wilkens, L.R., and Kolonel, L.N. (2000). Intake of flavonoids and lung cancer. J Natl Cancer Inst 92, 154-160 10.1093/jnci/92.2.154.
[24] Liyanage, U.K., Moore, T.T., Joo, H.G., Tanaka, Y., Herrmann, V., Doherty, G., Drebin, J.A., Strasberg, S.M., Eberlein, T.J., Goedegebuure, P.S., (2002). Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169, 2756-2761 .
[25] Lohr, F., Hu, K., Haroon, Z., Samulski, T.V., Huang, Q., Beaty, J., Dewhirst, M.W., and Li, C.Y. (2000). Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy. Mol Ther 2, 195-203 10.1006/mthe.2000.0114.
[26] Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P., and Bronte, V. (2008). Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222, 162-179 10.1111/j.1600-065X.2008.00602.x.
[27] Markiewicz, D.A., Schultz, D.J., Haas, J.A., Harris, E.E., Fox, K.R., Glick, J.H., and Solin, L.J. (1996). The effects of sequence and type of chemotherapy and radiation therapy on cosmesis and complications after breast conservation therapy. Int J Radiat Oncol Biol Phys 35, 661-668 10.1016/0360-3016(96)00171-X.
[28] McCahill, L.E., Privette, A., James, T., Sheehey-Jones, J., Ratliff, J., Majercik, D., Krag, D.N., Stanley, M., and Harlow, S. (2009). Quality measures for breast cancer surgery: initial validation of feasibility and assessment of variation among surgeons. Arch Surg 144, 455-462 ; discussion 462–463.
[29] Ogawa, K., Hirai, M., Katsube, T., Murayama, H., Hamaguchi, K., Shimakawa, T., Naritake, Y., Hosokawa, T., and Kajiwara, T. (2000). Suppression of cellular immunity by surgical stress. Surgery 127, 329-336 10.1067/msy.2000.103498.
[30] Ortiz-Andrade, R.R., Sanchez-Salgado, J.C., Navarrete-Vazquez, G., Webster, S.P., Binnie, M., Garcia-Jimenez, S., Leon-Rivera, I., Cigarroa-Vazquez, P., Villalobos-Molina, R., and Estrada-Soto, S. (2008). Antidiabetic and toxicological evaluations of naringenin in normoglycaemic and NIDDM rat models and its implications on extra-pancreatic glucose regulation. Diabetes Obes Metab 10, 1097-1104 10.1111/j.1463-1326.2008.00869.x.
[31] Page, G.G., and Ben-Eliyahu, S. (1997). Increased surgery-induced metastasis and suppressed natural killer cell activity during proestrus/estrus in rats. Breast Cancer Res Treat 45, 159-167 10.1023/A:1005826403235.
[32] Pulaski, B.A., and Ostrand-Rosenberg, S. (2001). Mouse 4T1 breast tumor model. Curr Protoc Immunol Chapter 20, Unit 20.2 .
[33] Pulaski, B.A., Terman, D.S., Khan, S., Muller, E., and Ostrand-Rosenberg, S. (2000). Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res 60, 2710-2715 .
[34] Rosenberg, S.A. (2001). Progress in human tumour immunology and immunotherapy. Nature 411, 380-384 10.1038/35077246.
[35] Salo, M. (1992). Effects of anaesthesia and surgery on the immune response. Acta Anaesthesiol Scand 36, 201-220 10.1111/j.1399-6576.1992.tb03452.x.
[36] Shafir, M., Bekesi, J.G., Papatestas, A., Slater, G., and Aufses, A.H. (1980). Preoperative and Postoperative Immunological Evaluation of Patients with Colorectal-Cancer. Cancer 46, 700-705
[37] Shenkier, T., Weir, L., Levine, M., Olivotto, I., Whelan, T., and Reyno, L. (2004). Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ 170, 983-994 10.1503/cmaj.1030944.
[38] So, F.V., Guthrie, N., Chambers, A.F., Moussa, M., and Carroll, K.K. (1996). Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr Cancer 26, 167-181 10.1080/01635589609514473.
[39] Townsend, S.E., and Allison, J.P. (1993). Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259, 368-370 10.1126/science.7678351.
[40] van der Bij, G.J., Oosterling, S.J., Bogels, M., Bhoelan, F., Fluitsma, D.M., Beelen, R.H., Meijer, S., and van Egmond, M. (2008). Blocking alpha2 integrins on rat CC531s colon carcinoma cells prevents operation-induced augmentation of liver metastases outgrowth. Hepatology 47, 532-543 10.1002/hep.22013.
[41] Whiteside, T.L. (2006). Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16, 3-15 10.1016/j.semcancer.2005.07.008.
[42] Yang, Y., Xu, Y., Xia, T., Chen, F., Zhang, C., Liang, W., Lai, L., and Fang, X. (2011). A single-molecule study of the inhibition effect of Naringenin on transforming growth factor-beta ligand-receptor binding. Chem Commun (Camb) 47, 5440-5442 10.1039/c1cc10778j.